Lunardi Andrea, Varmeh Shohreh, Chen Ming, Taulli Riccardo, Guarnerio Jlenia, Ala Ugo, Seitzer Nina, Ishikawa Tomoki, Carver Brett S, Hobbs Robin M, Quarantotti Valentina, Ng Christopher, Berger Alice H, Nardella Caterina, Poliseno Laura, Montironi Rodolfo, Castillo-Martin Mireia, Cordon-Cardo Carlos, Signoretti Sabina, Pandolfi Pier Paolo
Cancer Research Institute, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Cancer Biology and Genetics Program, Sloan Kettering Institute, Division of Urology, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Cancer Discov. 2015 May;5(5):550-63. doi: 10.1158/2159-8290.CD-13-1050. Epub 2015 Feb 4.
The ETS family of transcription factors has been repeatedly implicated in tumorigenesis. In prostate cancer, ETS family members, such as ERG, ETV1, ETV4, and ETV5, are frequently overexpressed due to chromosomal translocations, but the molecular mechanisms by which they promote prostate tumorigenesis remain largely undefined. Here, we show that ETS family members, such as ERG and ETV1, directly repress the expression of the checkpoint kinase 1 (CHK1), a key DNA damage response cell-cycle regulator essential for the maintenance of genome integrity. Critically, we find that ERG expression correlates with CHK1 downregulation in human patients and demonstrate that Chk1 heterozygosity promotes the progression of high-grade prostatic intraepithelial neoplasia into prostatic invasive carcinoma in Pten(+) (/-) mice. Importantly, CHK1 downregulation sensitizes prostate tumor cells to etoposide but not to docetaxel treatment. Thus, we identify CHK1 as a key functional target of the ETS proto-oncogenic family with important therapeutic implications.
Genetic translocation and aberrant expression of ETS family members is a common event in different types of human tumors. Here, we show that through the transcriptional repression of CHK1, ETS factors may favor DNA damage accumulation and consequent genetic instability in proliferating cells. Importantly, our findings provide a rationale for testing DNA replication inhibitor agents in ETS-positive TP53-proficient tumors.
ETS转录因子家族反复被认为与肿瘤发生有关。在前列腺癌中,ETS家族成员,如ERG、ETV1、ETV4和ETV5,由于染色体易位而经常过度表达,但其促进前列腺肿瘤发生的分子机制在很大程度上仍不清楚。在这里,我们表明,ETS家族成员,如ERG和ETV1,直接抑制检查点激酶1(CHK1)的表达,CHK1是维持基因组完整性所必需的关键DNA损伤反应细胞周期调节因子。至关重要的是,我们发现人类患者中ERG的表达与CHK1的下调相关,并证明Chk1杂合性促进Pten(+)/(-)小鼠中高级别前列腺上皮内瘤变进展为前列腺浸润癌。重要的是,CHK1下调使前列腺肿瘤细胞对依托泊苷敏感,但对多西他赛治疗不敏感。因此,我们确定CHK1是ETS原癌基因家族的关键功能靶点,具有重要的治疗意义。
ETS家族成员的基因易位和异常表达在不同类型的人类肿瘤中是常见事件。在这里,我们表明,通过对CHK1的转录抑制,ETS因子可能有利于DNA损伤积累以及增殖细胞中随之而来的遗传不稳定。重要的是,我们的发现为在ETS阳性且TP53功能正常的肿瘤中测试DNA复制抑制剂提供了理论依据。